Your donation matters! Dr. Stachler of @UCSF expressed gratitude for the research funding he was awarded.
To donate in support of esophageal cancer research, visit: https://t.co/lyuw3BWwNv
To read more about Dr. Stachler's research, please visit: https://t.co/42GNU8MOrd
Interesting study showing many cases of "recurrent" Barrett's esophagus after endoscopic therapy is actually residual disease. Highly collaborative effort!!
Clinical and Translational Gastroenterology https://t.co/dUl1aYw6b1
Excited to show some of our work in spatial profiling. This was just the pilot phase of the experiment, but the results look promising.
https://t.co/fTRForIrEv
Frustrating but after 2 yrs, three rounds of review, and 2/3 positive reviewers our manuscript has been rejected at Nature Genetics. Not sure this is sustainable. On the plus side, it has given us a chance to update the BioRxiv version. Check it out.
https://t.co/6Kp2sRuTC8
If you are going to submit a manuscript for publication, please review for grammar and labeling errors. Mistakes will happen (my grammar is terrible) but they shouldn’t make the paper unreadable. 😡
@MattGosseMD@GIPathJC Our clinical information was somewhat limited (no BE length) and in the retrospective cohort controlled for age. We didn’t identify any other factors that correlated with staining. A deep dive into the histology could be interesting to see if there is something there.
@GIPathJC Thank you for having me. I hope our study is useful. We have several other interesting projects in the pipeline looking at genomic and epigenomic alterations as biomarkers. Always looking for potential collaborations!
@GILiverPancreas @GIPathJC In our study no patient had a visible lesion, though as endoscopies improve more and more low-grade dysplasia is visible. We don't use that as a criteria but I can't say for certain what the gastroenterologists use to make their final decision
@GIPathJC That is a really good question and one that I don't think is fully answered. In our study we tried to stain every BE block we could and counted the endoscopy + if any one of them had abnormal p53. We definitely had cases were not every block was positive.
@GIPathJC I could see more requests coming in. I think if you take our study in the context of all of the previous work, there is now reasonable evidence for it. Any different clone should be tested to see if they perform similarly.
@GIPathJC Like any more complex interpretation (HER2,...) it takes a little practice, but we did not run into too many difficulties. There were cases termed "indefinite staining" with some 2-3+ but <50%. We counted all of those as negative which seemed to work better than a lower cutoff
@GIPathJC In areas of increased proliferation one can see slightly elevated p53 staining. In those cases it helps if you can see the staining outside of the normal proliferative zone
@GIPathJC Its interesting, people have been using p53 as a marker for dysplasia but in reality I think it is a marker for progression risk not necessarily dysplasia. However, if one assumes the vast majority of non-dysplastic BE is low risk, using it as help in IND diagnosis is reasonable